Stock Research for FATE

FATE

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

FATE Stock Chart & Research Data

The FATE chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the FATE chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


FATE Due diligence Resources & Stock Charts

The FATE stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View FATE Detailed Price Forecast - CNN Money CNN View FATE Detailed Summary - Google Finance
Yahoo View FATE Detailed Summary - Yahoo! Finance Zacks View FATE Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View FATE Trends & Analysis - Trade-Ideas Barrons View FATE Major Holders - Barrons
NASDAQ View FATE Call Transcripts - NASDAQ Seeking View FATE Breaking News & Analysis - Seeking Alpha
Spotlight View FATE Annual Report - CompanySpotlight.com OTC Report View FATE OTC Short Report - OTCShortReport.com
TradeKing View FATE Fundamentals - TradeKing Charts View FATE SEC Filings - Bar Chart
WSJ View Historical Prices for FATE - The WSJ Morningstar View Performance/Total Return for FATE - Morningstar
MarketWatch View the Analyst Estimates for FATE - MarketWatch CNBC View the Earnings History for FATE - CNBC
StockMarketWatch View the FATE Earnings - StockMarketWatch MacroAxis View FATE Buy or Sell Recommendations - MacroAxis
Bullish View the FATE Bullish Patterns - American Bulls Short Pains View FATE Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View FATE Stock Mentions - StockTwits PennyStocks View FATE Stock Mentions - PennyStockTweets
Twitter View FATE Stock Mentions - Twitter Invest Hub View FATE Investment Forum News - Investor Hub
Yahoo View FATE Stock Mentions - Yahoo! Message Board Seeking Alpha View FATE Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for FATE - SECform4.com Insider Cow View Insider Transactions for FATE - Insider Cow
CNBC View FATE Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for FATE - OTC Markets
Yahoo View Insider Transactions for FATE - Yahoo! Finance NASDAQ View Institutional Holdings for FATE - NASDAQ


Stock Charts

FinViz View FATE Stock Insight & Charts - FinViz.com StockCharts View FATE Investment Charts - StockCharts.com
BarChart View FATE Stock Overview & Charts - BarChart Trading View View FATE User Generated Charts - Trading View




Latest Financial News for FATE


Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Posted on Monday April 22, 2024

Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refractory B-cell Malignancies to be Highlighted Patient Enrollment Initiated in Phase 1 Study of FT819 Off-the-shelf, CD19-targeted, iPSC-derived CAR T-cell Therapy for Systemic Lupus Erythematosus SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage bio


Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
Posted on Friday April 05, 2024

Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.


Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
Posted on Wednesday April 03, 2024

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 2:15 PM ET. A live webcast


Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Posted on Tuesday April 02, 2024

SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that on April 1, 2024 the Company granted restricted stock units (RSUs) representing 6,400 shares of its common stock to one newly-hired non-executive employee. The grant was approved


Stock Market & Investing Books

Enter a stock symbol to view the stock details.